| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Kenvue Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.48 |
| 52 Week High | US$25.81 |
| 52 Week Low | US$17.30 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -27.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| J4D | DE Personal Products | DE Market | |
|---|---|---|---|
| 7D | n/a | 2.1% | -1.4% |
| 1Y | n/a | -0.9% | 2.2% |
Return vs Industry: Insufficient data to determine how J4D performed against the German Personal Products industry.
Return vs Market: Insufficient data to determine how J4D performed against the German Market.
Price Volatility
| J4D volatility | |
|---|---|
| J4D Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: J4D has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine J4D's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 22,000 | Thibaut Mongon | www.kenvue.com |
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Kenvue Inc. Fundamentals Summary
| J4D fundamental statistics | |
|---|---|
| Market cap | €33.76b |
| Earnings (TTM) | €1.56b |
| Revenue (TTM) | €14.47b |
21.7x
P/E Ratio2.3x
P/S RatioIs J4D overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J4D income statement (TTM) | |
|---|---|
| Revenue | US$15.44b |
| Cost of Revenue | US$6.80b |
| Gross Profit | US$8.64b |
| Other Expenses | US$6.98b |
| Earnings | US$1.66b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 0.87 |
| Gross Margin | 55.96% |
| Net Profit Margin | 10.77% |
| Debt/Equity Ratio | 73.9% |
How did J4D perform over the long term?
See historical performance and comparisonDividends
4.3%
Current Dividend Yield44%
Payout RatioDoes J4D pay a reliable dividends?
See J4D dividend history and benchmarks| Kenvue dividend dates | |
|---|---|
| Ex Dividend Date | May 07 2024 |
| Dividend Pay Date | May 22 2024 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 20 days |
Does J4D pay a reliable dividends?
See J4D dividend history and benchmarks